成人神经外科干预患者药物性血栓预防预防静脉血栓栓塞
该系统评价检索至2018年4月的三个数据库,纳入7项随机对照试验和3项非随机对照研究,评估神经外科患者药物性与非药物性血栓预防的疗效与安全性。低确定性证据提示药物性血栓预防可能降低无症状近端深静脉血栓风险(RR 0.50,95%CI 0.30-0.84),但对患者重要结局的影响确定性很低。
要点
- 药物性血栓预防可能降低无症状近端深静脉血栓风险(RR 0.50,95%CI 0.30-0.84,低确定性)
- 对死亡率、症状性肺栓塞、无症状远端深静脉血栓及再手术的效应均不确定
- 随机对照试验和非随机对照研究中出血风险均不确定
核心结论
- 在神经外科手术患者中,低确定性证据提示药物性血栓预防对预防无症状(筛查发现的)近端深静脉血栓有益,但其对患者重要结局的影响确定性很低。
研究设计与样本
- 系统评价检索三个数据库至2018年4月,纳入随机对照试验和非随机对照研究,由独立评价者采用GRADE方法评估证据确定性。
- 共纳入7项随机对照试验和3项非随机对照研究。
主要发现
- 无研究报告症状性近端和远端深静脉血栓;2项随机对照试验报告了筛查发现的近端和远端深静脉血栓,并作为最接近的替代结局。
- 这2项随机对照试验提示药物性血栓预防可能降低无症状近端深静脉血栓风险(RR 0.50,95%CI 0.30-0.84,低确定性)。
- 随机对照试验中死亡率(RR 1.27,95%CI 0.57-2.86,低确定性)、症状性肺栓塞(RR 0.84,95%CI 0.03-27.42,极低确定性)、无症状远端深静脉血栓(RR 0.54,95%CI 0.27-1.08,极低确定性)和再手术(RR 0.43,95%CI 0.06-2.84,极低确定性)的 findings 不确定。
- 非随机对照研究中药物性预防对死亡率(RR 0.72,95%CI 0.46-1.13,低确定性)和肺栓塞(RR 0.18,95%CI 0.01-3.76)的影响不确定。
- 出血风险在随机对照试验(RR 1.57,95%CI 0.70-3.50,低确定性)和非随机对照研究(RR 1.45,95%CI 0.30-7.12,极低确定性)中均不确定。
局限性
- 无研究报告症状性近端和远端深静脉血栓,仅以2项随机对照试验的筛查发现深静脉血栓作为替代结局。
- 死亡率、症状性肺栓塞、无症状远端深静脉血栓、再手术及出血等结局的证据确定性为低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of pharmacologic prophylaxis for venous thromboembolism in patients undergoing neurosurgical intervention remains uncertain. We reviewed the efficacy and safety of pharmacologic compared with nonpharmacologic thromboprophylaxis in neurosurgical patients. Three databases were searched through April 2018, including those for randomized controlled trials (RCTs) and for nonrandomized controlled studies (NRSs). Independent reviewers assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seven RCTs and 3 NRSs proved eligible. No studies reported on symptomatic proximal and distal deep vein thrombosis (DVT). Two RCTs reported on screening-detected proximal and distal DVTs. We used the findings of these 2 RCTs as the closest surrogate outcomes to inform the proximal and distal DVT outcomes. These 2 RCTs suggest that pharmacologic thromboprophylaxis may decrease the risk of developing asymptomatic proximal DVT (relative risk [RR], 0.50; 95% confidence interval [CI], 0.30-0.84; low certainty). Findings were uncertain for mortality (RR, 1.27; 95% CI, 0.57-2.86; low certainty), symptomatic pulmonary embolism (PE) (RR, 0.84; 95% CI, 0.03-27.42; very low certainty), asymptomatic distal DVT (RR, 0.54; 95% CI, 0.27-1.08; very low certainty), and reoperation (RR, 0.43; 95% CI, 0.06-2.84; very low certainty) outcomes. NRSs also reported uncertain findings for whether pharmacologic prophylaxis affects mortality (RR, 0.72; 95% CI, 0.46-1.13; low certainty) and PE (RR, 0.18; 95% CI, 0.01-3.76). For risk of bleeding, findings were uncertain in both RCTs (RR, 1.57; 95% CI, 0.70-3.50; low certainty) and NRSs (RR, 1.45; 95% CI, 0.30-7.12; very low certainty). In patients undergoing neurosurgical procedures, low certainty of evidence suggests that pharmacologic thromboprophylaxis confers benefit for preventing asymptomatic (screening-detected) proximal DVT with very low certainty regarding its impact on patient-important outcomes.
引用
- Yepes-Nuñez JJ, Rajasekhar A, Rahman M, et al. Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism. Blood Adv. 2020. PMID: 32574367. doi:10.1182/bloodadvances.2020002195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。